14 Jun 2023
Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site
Author: admintech | Filed under: Press ReleaseHoth achieves milestone of multiple sites to host trial NEW YORK, June 14, 2023 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received written approval from the University of Texas MD Anderson Cancer…